My take after dwelling on the news last night.
A question I have is Scott’s presentation that all appeared to be on track for approval. Two days later not so. I would be steamed, if I were him, about my reputaion and be asking Momenta if they had any the warnings about the problem.
Nest question I have would be was Momenta aware of prior FDA warning of issues as some indicate they give warnings before the letter.
If they were not, why not? That could be a problem for Pfizer if they had not made us aware of prior warnings. Doing a google search they have had a lot of warnings on other drugs. PFE should well be aware of the standards to avoid this kind of problem.
If they made Momenta aware, then why would that not be mentioned as a potential issue prior to approval and what we were discussing with them. All the facts here are going to come out sooner or later once we find out what the FDA letter said.
Who picked PFE? Sandoz or Sandoz and us?
Next, the time frame they expect to correct the problem or problems.
Next any other possible alternatives to speed things up towards approval.
Any agreements that might or might not protect Momenta its shareholders for this delay. I would guess we suffer delay of potential large earned payments and therefore resulting lack of interest earned due to the lack os sales of the 40mg Glatopa drug.
We know there are multiple calls to out right buy our M923. hsIvig is in the wings along with other drugs. I am hanging tight waiting on the CC along with taking a deep breath.
Now is the time for straight clear answers as they know the facts.
Boing X 2
